Rallybio Corporation(NASDAQ:RLYB) 
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead program is RLYB212, a preclinical-stage monoclonal anti-HPA-1a antibody for t...
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 0.57
H 0.63
L 0.43
C 0.45
V 182,496
10EMA 0.45
20EMA 0.45
60EMA 0.45
120EMA 0.45
250EMA 0.45